mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines
Company to begin Phase 3 trial of mRNA-1083 in adults 50 years and above (October 4, 2023. Press Release from Moderna).
Of course, Moderna isn’t showing anyone that reactogenicity and safety …